New hope for blood cancer relapse: targeted combo aims to control disease
NCT ID NCT07024706
First seen Nov 01, 2025 · Last updated May 15, 2026 · Updated 26 times
Summary
This study tests a combination of two targeted drugs (acalabrutinib and venetoclax) for people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) whose cancer has returned after previous treatment. The goal is to see if this short-term therapy can control the disease again. About 80 adults who responded well to their first treatment and stayed in remission for at least two years will participate.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SMALL LYMPHOCYTIC LYMPHOMA (SLL) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Research Site
Boston, Massachusetts, 02215, United States
-
Research Site
Charlotte, North Carolina, 28204, United States
-
Research Site
Durham, North Carolina, 27705, United States
-
Research Site
Horn, 3580, Austria
-
Research Site
Brno, 625 00, Czechia
-
Research Site
Hradec Kralova, 50005, Czechia
-
Research Site
Ostrava, 708 502, Czechia
-
Research Site
Dublin, 7, Ireland
-
Research Site
Dublin, D08 NHY1, Ireland
-
Research Site
Lugo, 48022, Italy
-
Research Site
Meldola, 47014, Italy
-
Research Site
Milan, 20162, Italy
-
Research Site
Padua, 35128, Italy
-
Research Site
Roma, 00165, Italy
-
Research Site
Rome, 00168, Italy
-
Research Site
Torino, 10126, Italy
-
Research Site
Bydgoszcz, 85-168, Poland
-
Research Site
Krakow, 30-727, Poland
-
Research Site
Lodz, 93-513, Poland
-
Research Site
Lublin, 20-090, Poland
-
Research Site
Warsaw, 02-172, Poland
-
Research Site
Warsaw, 02-776, Poland
-
Research Site
Barcelona, 08041, Spain
-
Research Site
Barcelona, 8035, Spain
-
Research Site
Granada, 18014, Spain
-
Research Site
Madrid, 28031, Spain
-
Research Site
Madrid, 28034, Spain
-
Research Site
Madrid, 28041, Spain
-
Research Site
Majadahonda, 28222, Spain
Conditions
Explore the condition pages connected to this study.